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Abstract
The molecular details of Chlamydia trachomatis binding, entry, and spread are incompletely understood, but heparan
sulfate proteoglycans (HSPGs) play a role in the initial binding steps. As cell surface HSPGs facilitate the interactions of many
growth factors with their receptors, we investigated the role of HSPG-dependent growth factors in C. trachomatis infection.
Here, we report a novel finding that Fibroblast Growth Factor 2 (FGF2) is necessary and sufficient to enhance C. trachomatis
binding to host cells in an HSPG-dependent manner. FGF2 binds directly to elementary bodies (EBs) where it may function
as a bridging molecule to facilitate interactions of EBs with the FGF receptor (FGFR) on the cell surface. Upon EB binding,
FGFR is activated locally and contributes to bacterial uptake into non-phagocytic cells. We further show that C. trachomatis
infection stimulates fgf2 transcription and enhances production and release of FGF2 through a pathway that requires
bacterial protein synthesis and activation of the Erk1/2 signaling pathway but that is independent of FGFR activation.
Intracellular replication of the bacteria results in host proteosome-mediated degradation of the high molecular weight
(HMW) isoforms of FGF2 and increased amounts of the low molecular weight (LMW) isoforms, which are released upon host
cell death. Finally, we demonstrate the in vivo relevance of these findings by showing that conditioned medium from C.
trachomatis infected cells is enriched for LMW FGF2, accounting for its ability to enhance C. trachomatis infectivity in
additional rounds of infection. Together, these results demonstrate that C. trachomatis utilizes multiple mechanisms to co-
opt the host cell FGF2 pathway to enhance bacterial infection and spread.
Citation: Kim JH, Jiang S, Elwell CA, Engel JN (2011) Chlamydia trachomatis Co-opts the FGF2 Signaling Pathway to Enhance Infection. PLoS Pathog 7(10):
e1002285. doi:10.1371/journal.ppat.1002285
Editor: Raphael H. Valdivia, Duke University, United States of America
Received November 23, 2010; Accepted August 10, 2011; Published October 6, 2011
Copyright:  2011 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the NIH (R01 AI073770). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jengel@medicine.ucsf.edu
Introduction
Chlamydia trachomatis, an obligate intracellular bacterium, is the
most common bacterial cause of sexually transmitted diseases and
non-congenital infertility in Western countries and the leading
cause of acquired blindness in developing countries (reviewed in
[1]). C. trachomatis serovars A–C cause eye disease, serovars D–K
cause genital tract infections, and serovars L1–L3 are associated
with lymphogranuloma venereum (LGV), a more invasive genital
tract disease. C. pneumoniae infections result in upper and lower
respiratory tract infections and have been linked to a growing
number of chronic diseases, including atherosclerosis, multiple
sclerosis, and Alzheimer’s disease. The capacity of Chlamydiae to
lead to infertility and blindness, their association with chronic
diseases, and the extraordinary prevalence and array of these
infections make them public concerns of primary importance.
All Chlamydia species share a dimorphic life cycle in which they
alternate between an extracellular, spore-like form, the elementary
body (EB), and an intracellular, metabolically active but non-
infectious form, the reticulate body (RB) [2]. Chlamydiae can
productively infect most cultured cells, suggesting that the
receptor(s) is widespread and/or that there are multiple receptors.
Although neither the bacterial ligand nor the host receptor(s) have
been definitively identified, it is thought that binding is a two step
process that involves an initial reversible interaction between the
EB and the host cell followed by high affinity irreversible binding
to a secondary receptor (reviewed in [3]).
After binding, Chlamydiae induce their uptake into non-
phagocytic cells through small-GTPase dependent reorganization
of the actin cytoskeleton to form microvillus-like structures
(reviewed in [4]). Both bacterial and host factors are implicated
in this process. These include (i) translocated actin recruiting
phosphoprotein (TARP), a chlamydial protein secreted into the
host cell cytosol upon bacterial binding, (ii) the host tyrosine
kinases platelet-derived growth factor receptor (PDGFR)-b and
Abl kinase, and (iii) other host actin cytoskeleton regulatory
proteins that are recruited to TARP and/or to PDGFR [5,6,7].
Following entry, EBs are sequestered within a membrane-bound
compartment, termed a vacuole or inclusion, which quickly
dissociates from the endo-lysosomal pathway and avoids fusion
with phagosomes (reviewed in [8]). Subsequently, EBs differentiate
into RBs, which replicate by binary fission within the enlarging
inclusion over a 12–72 hr time period. In response to an as yet
unknown signal, RBs redifferentiate into EBs and are released
from the host cell through cell lysis or active extrusion [9], where
they can initiate secondary rounds of infection in neighboring cells.
Chlamydia infection alters the transcription of many host genes,
including pro-inflammatory cytokines, and regulators of apoptosis,
PLoS Pathogens | www.plospathogens.org 1 October 2011 | Volume 7 | Issue 10 | e1002285cell differentiation, and the cytoskeleton [10,11]. The combination
of tissue destruction and host inflammatory responses is at least
partially responsible for the devastating long-term consequences of
Chlamydia infection [12].
For many C. trachomatis serovars, the initial reversible binding step
is thought to involve binding to host heparan sulfate proteoglycans
(HSPGs), as addition of excess heparin or heparan sulfate but not
chondroitin sulfate, inhibits binding [13,14,15]. HSPGs are
extraordinarily heterogeneous structures that are composed of a
linear array of repeating dissacharides covalently linked to various
core proteins and are variably sulfated [16]. A large number of
growth factors, cytokines, and differentiation factors, as well as
various classes of cell surface receptors, extracellular matrix
proteins, and enzymes, bind to HSPGs [17]. Prominent among
these is fibroblast growth factor 2 (FGF2; also known as basic
fibroblast growth factor), one of the 23 FGF family members.
FGF2 is critical during development and can also mediate many
cellular responses in adult tissues by binding to and activating the
receptor tyrosine kinases FGFR1-FGFR4 [18]. FGF2 itself is
heterogeneous; it is expressed as five different isoforms (34, 24,
22.5, 22, and 18 kDa isoforms) that result from alternative
translational start sites within a single mRNA. The 18 kDa
isoform can be further processed into a 16 kDa protein, which has
identical properties [19]. Only the 16/18 kDa isoforms are
secreted, where they bind to cell surface HSPGs, functioning in
a paracrine and autocrine manner to activate FGF receptor
(FGFR) family members. In contrast, the larger FGF2 isoforms,
translated from non-canonical CUG start codons, have nuclear
localization signals and are found primarily in the nucleus; their
functions remain incompletely elucidated [20,21]. Although FGF2
dimers can bind to and activate FGFR, binding of HSPGs
stabilizes activated ligand-bound dimeric FGFR [22,23,24]. FGFR
activation leads to recruitment and tyrosine phosphorylation of the
docking proteins FGFR substrate (FRS) 2a and FRS2b, as well as
SHC1, followed by recruitment and activation of Grb2, SOS, Ras,
mitogen-activated protein kinase (MAPK), and phosphatidyl
inositol-3 kinase (PI3K) [25,26].
In this work, we examined the effect of HSPG-associated
growth factors on C. trachomatis infection. We report that C.
trachomatis serovar L2 EBs bind to FGF2, which facilitates bacterial
binding, and that FGF2 promotes internalization of EBs via
FGFR. In addition, C. trachomatis stimulates FGF2 transcription,
production, and release to facilitate additional rounds of infection.
Upregulation of FGF2 is independent of FGFR activation but
involves bacterial protein synthesis and activation of the
extracellular signal-regulated kinase (Erk) 1/2 pathway. Many of
these findings were also observed with C. trachomatis serovar E,
whose binding was also enhanced by FGF2 in an HSPG-
dependent manner. Thus, C. trachomatis utilizes multiple mecha-
nisms to co-opt the host cell FGF2 pathway to enhance bacterial
infection and spread.
Results
FGF2 is sufficient to stimulate C. trachomatis binding and
vacuole formation
Given the previously published involvement of HSPGs on initial
steps in C. trachomatis binding [5,27], we tested whether HSPG-
dependent growth factors enhance C. trachomatis binding to
cultured cervical cells. HeLa cells were serum-starved for 2 hrs
and then infected with C. trachomatis serovar L2 in serum-free
media (SFM), in the presence of 10% fetal bovine serum (FBS), or
HSPG-dependent growth factors. Binding and vacuole formation
were measured at 1 hr post-infection (hpi) and 20 hpi, respective-
ly. Addition of 10% FBS or purified FGF2 stimulated binding and
vacuole formation ,2–3 fold (Figs 1A–C). In contrast, neither
PDGF-BB, FGF-1, FGF-10, Vascular Endothelial Growth Factor
(VEGF), Epidermal Growth Factor (EGF), nor heparin-binding
EGF-like growth factor (HB-EGF) significantly enhanced EB
binding or vacuole formation (Figs 1A, B). FGF2 increased C.
trachomatis binding in a dose-dependent, saturable manner, with
half-maximal binding observed at ,50 ng/mL of FGF2 (Fig S1A).
We also observed that FGF2 was sufficient to enhance C.
trachomatis vacuole formation in H292 cells, a human lung
epithelial cell line (Fig S1B).
As FGF2-FGFR interactions are stabilized through binding to
HSPGs, we tested whether FGF2-stimulated C. trachomatis binding
is HSPG-dependent (Fig 1C). HeLa cells were treated with
heparinase for 2 hrs in SFM. After washing to remove the
heparinase, the cells were infected for 1 hr with C. trachomatis in the
presence or absence of FGF2 or serum. Pre-treatment of cells with
heparinase significantly decreased FBS- or FGF2-stimulated
binding (p,0.005), but had no statistically significant effect on
EB binding in SFM, ruling out non-specific effects (Fig 1C). In
control experiments, we verified that heparinase-treatment was
effective, as surface staining with an anti-heparan sulfate antibody
was decreased by 60% under the conditions of our experiments
(Fig S2). The residual stimulatory effect of FGF2 after heparinase
treatment may reflect incomplete enzymatic removal or may
represent HSPG-independent FGF2 stimulation. Nonetheless,
these results show that FGF2 is sufficient to enhance C. trachomatis
binding in an HSPG-sensitive manner and that FGF2-mediated C.
trachomatis binding leads to productive infection.
FGF2 binds directly to EBs and facilitates binding to HeLa
cells
As FGF2 is known to bind to both FGFR and to HSPGs on the
cell surface, it is possible that FGF2 could facilitate EB binding
through direct interactions with C. trachomatis and with FGFR,
thereby functioning as a bridging molecule to bring EBs to the host
cell surface. Alternatively, FGF2 could indirectly enhance C.
trachomatis binding by upregulating a host cell receptor or
stimulating its endocytosis as a consequence of FGFR activation.
Author Summary
Chlamydia trachomatis is an obligate intracellular bacteri-
um that is an important cause of human disease, including
sexually transmitted diseases and acquired blindness in
developing countries. The inability to carry out conven-
tional genetic manipulations limits our understanding of
the mechanisms of C. trachomatis binding, entry, and
spread. Previous studies have shown that heparan sulfate
proteoglycans (HSPGs) play a role in early binding events.
As cell surface HSPGs facilitate the interactions of many
growth factors with their receptors, we investigated
whether HSPG-associated growth factors affect C. tracho-
matis binding or entry. Here, we report the novel finding
that Fibroblast Growth Factor 2 (FGF2), a ubiquitously
expressed growth factor, enhances C. trachomatis binding
to host cells in an HSPG-dependent manner. Furthermore,
C. trachomatis infection stimulates production and release
of FGF2 through distinct signaling pathways. Released
FGF2 is sufficient to enhance the subsequent rounds of
infection. Together, these results demonstrate that C.
trachomatis utilizes multiple mechanisms to co-opt the
host cell FGF2 pathway that sets up a positive feedback
loop to enhance bacterial infection and spread.
C. trachomatis Co-opts FGF2 to Enhance Infection
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surface bound EBs, whereas in the second model, FGF2 binding
could be spatially distinct from EB binding. We therefore
examined whether FGF2 colocalizes with C. trachomatis at the cell
surface. HeLa cells were serum starved and infected with C.
trachomatis for 45 min in the presence of FGF2, or as a negative
control, with FGF1, and co-localization of EBs with FGF1 or
FGF2 was quantified by immunofluorescence (IF) microscopy. As
shown in Fig 2, ,35% of surface bound EBs colocalized with
FGF2, whereas only ,5% of surface bound EBs were found in
association with FGF1 (p,0.001).
Figure 1. FGF2 stimulates C. trachomatis L2 binding in an HSPG-
dependent manner. (A, B) HeLa cells were serum starved for 2 hr and
then infected with C. trachomatis L2 in SFM, in FBS-containing media, or
in SFM supplemented with the indicated growth factors (100 ng/mL)
for 1 hr. Binding and vacuole formation was quantified at 1 hpi (A) and
20 hpi (B), respectively. Shown is the mean 6 SEM of three
independent experiments normalized to SFM. *** p,0.001 (C) HeLa
cells were treated with heparinase for 2 hr in SFM and infected for 1 hr
with C. trachomatis L2 either in SFM, in FBS-containing media, or in SFM
supplemented with FGF2 (100 ng/mL). Shown is the mean binding 6
SEM normalized to mock-treated cells infected in SFM from four
independent experiments. * p,0.05, *** p,0.001
doi:10.1371/journal.ppat.1002285.g001
Figure 2. FGF2 co-localizes with cell surface bound EBs. HeLa
cells were infected for 1 hr with C. trachomatis L2 in SFM supplemented
with FGF1 (left panels; 100 ng/mL) or with FGF2 (right panels; 100 ng/
mL). (A) Cells were fixed and stained with FGF1 antibody (left panels) or
FGF2 antibody (right panels). Cell surface associated EBs and host cell
nuclei were visualized by DAPI (blue) staining. Arrows point to EBs. (B)
Co-localization of EBs with FGF1 or FGF2 was quantified from at least 8
different fields. The data are expressed as a mean percentage of FGF-
associated bacteria (6 SEM) compared to total bacteria. *** p,0.001
doi:10.1371/journal.ppat.1002285.g002
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bind directly to EBs in vitro. Renograffin-purified EBs were
incubated with FGF2o rF G F 1i nS F Ma t3 7 uCf o r1 h r ,
centrifuged onto coverslips, fixed, stained with antibodies to
FGF1 or FGF2, and examined by IF. In the absence of either
growth factor, very little antibody to FGF1 or FGF2 bound to
purified EBs (Fig 3A and B). Surprisingly, addition of purified
FGF2 from two different sources increased the frequency of
anti-FGF2 staining of EBs from less than 10% to 50% (Fig 3C
and data not shown; p,0.001). In contrast, only ,5% of FGF1
associated with EBs, and this fraction was not enhanced upon
addition of exogenous FGF1 (Figs 3A and 3C). In control
experiments, anti-FGF1 antibody recognized FGF1 bound to
the cell surface (Fig 2A). Co-localization of FGF2 with purified
EBs was not diminished by pre-treatment of EBs with
heparinase (Fig 3D, P.0.05).
As a further test of specificity, we examined whether neutralizing
antibodies against FGF2 decreased FGF2 binding to EBs. EBs were
incubated with SFM containing 100 ng/mL FGF2 in the presence
of the indicated neutralizing antibody for 1 hr and then examined
for FGF2 binding to EBs by IF. As shown in Fig 3E, addition of
FGF2 antibodies decreased FGF2 binding to EBs by approximately
2-fold compared to incubation with an isotype-matched control
antibody or in the absence of antibody (p,0.001). Together, these
results suggest that EBs can bind specifically to FGF2 to facilitate
binding to the surface of host cells. We note that these experiments
do not eliminate the possibility that FGF2 may also stimulate C.
trachomatis binding through additional mechanisms.
Figure 3. FGF2 binds to renograffin-purified C. trachomatis L2 EBs. Renograffin-purified EBs were incubated with 100 ng/mL of FGF1 (A) or
FGF2 (B) in SFM containing 0.1% BSA for 1 hr at 37uC. The EB-FGF mixture was centrifuged onto coverslips, fixed, and stained with DAPI (to visualize
the EBs) and FGF1 antibody (A) or FGF2 antibody (B). Red arrows in the enlarged images show co-localization of FGF2 with EBs. (C) Co-localization of
EBs with FGF1 or FGF2 was quantified from at least 8 different fields. The data are expressed as a mean percentage of FGF-associated bacteria (6
SEM) compared to total bacteria. *** p,0.001 compared to the absence of growth factor (D) EBs that had been either mock- or heparinase-treated for
2 hrs were incubated with FGF2 as described in 3A. Co-localization of EBs with FGF2 was quantified as described in 3C. The values are expressed as a
mean percentage (6 SEM) of FGF2-associated bacteria compared to total bacteria from three independent experiments. The data are normalized to
the mock treated EBs. The difference in FGF2 binding between mock- and heparinase-treated EBs was not statistically significant (P.0.05) (E) EBs and
FGF2 were incubated in the presence of isotype matched Goat IgG or FGF2 neutralizing antibody for 1 hr. The FGF2-antibody mixture was
centrifuged onto coverslips, fixed, and stained. The values are expressed as a mean percentage (6 SEM) of FGF2-associated bacteria compared to
total bacteria. The data are normalized to the no antibody control. *** p,0.001
doi:10.1371/journal.ppat.1002285.g003
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binding
The ability of exogenous FGF2 to stimulate C. trachomatis
binding led us to examine whether endogenous FGF2 contributed
to C. trachomatis binding. Since FGF2 is expressed as 5 different
isoforms that result from alternative translation initiation sites (not
from differential splicing), we used a short hairpin RNA (shRNA)
directed against a region common to all isoforms. Cells were
transfected with an shRNA against FGF2 or against GFP (control)
(Fig 4A, left panel). Infections were performed in SFM, as the
presence of exogenous FGF2 in serum would likely mask the
effects of RNAi depletion. Under conditions where total FGF2 was
depleted by 60% as determined by densitometry, we observed a
40% decrease in C. trachomatis binding compared to cells treated
with a control (GFP) shRNA (p,0.01; Fig 4A, right panel). These
results suggest that endogenous FGF2 contributes to C. trachomatis
binding.
FGFR is activated upon infection and recruited to cell
associated C. trachomatis
Our results predict that FGF2-mediated binding of EBs to the
host cell surface should result in activation of FGFR and
downstream signaling pathways. FGF2 binds to and activates
most isoforms of FGFR (FGFR1 IIIb and IIIc, FGFR2 IIIc,
FGFR3 IIIc, and FGFR4)[28,29,30], resulting in activation of
their tyrosine kinase activity, autophosphorylation of tyrosine 653/
654, and phosphorylation of the scaffolding protein, FRS2a,
which is constitutively associated with FGFR. Upon tyrosine
phosphorylation, FRS2a functions as a site for coordinated
assembly of a multi-protein signaling complex, including Grb
and Shp2, leading to activation of the PI3K and the Ras/Erk
pathways [26].
We used several approaches to determine whether FGFR is
activated upon C. trachomatis binding. First, we examined by IF
microscopy whether activated FGFR (pFGFR) co-localized with
cell surface bound EBs, using a monoclonal antibody that
specifically recognizes phosphorylation of the conserved tyro-
sines at 653/654. IF analysis revealed that pFGFR was found
with cell-associated EBs (Fig 4B). We were unable to detect
changes in the localization of total FGFR1 or FGFR2 (data not
shown), possibly because only a small fraction of total cellular
FGFR is recruited and phosphorylated at the site of EB binding.
Second, since activation of FGFR is required for FRS2a
phosphorylation, we used IF microscopy to determine whether
phosphorylated FRS2a is recruited to the site of C. trachomatis
binding. Indeed, an antibody directed against phosphotyrosine
436 of FRS2a (pFRS2a) co-localized with cell-surface bound
E B s( F i g4 B ,r i g h tp a n e l s ) .T h i r d ,w em e a s u r e da c t i v a t i o no f
FRS2a by immunoblotting with an antibody to pFRS2a.A t
45 min pi, increased phospho-FRS2a was detected in C.
trachomatis-infected HeLa cells (Fig 4C, lower panel), at levels
similar to what is observed at 5 min after addition of FGF2 to
serum starved HeLa cells (Fig 4C, upper panel). C. trachomatis-
induced FRS2a phosphorylation was blocked by the FGFR
inhibitor, PD173074 (Figs 4C and 4D), confirming that FRS2a
phosphorylation was a result of C. trachomatis-activation of FGFR.
Depletion of endogenous FGF2 by shRNA reduced the percent
of EBs colocalized with pFGFR from 35% to 15%, suggesting
that recruitment of pFGFR to the site of C. trachomatis binding is
FGF2-dependent (Fig 4E). Together, these findings indicate that
FGF2 mediated C. trachomatis binding is associated with the
activation and recruitment of phosphorylated FGFR and
FRS2a.
FGFR and PDGFR have redundant roles in C. trachomatis
entry
There is evidence of cross-talk between growth factor receptors;
for example, PDGFR has been shown to activate FGFR [31].
Since we recently reported that PDGFR contributes to C.
trachomatis binding and internalization [5], we examined the
possible interrelationship between FGFR and PDGFR signaling
pathways during C. trachomatis infection in SFM using pharmaco-
logical inhibitors. In control experiments, we established that
AG1296, a PDGFR inhibitor, blocked PDGF-dependent PDGFR
activation (data not shown) but had no effect on FGF2 dependent
activation of FRS2a (Fig 4C, upper panel). Importantly, AG1296
did not inhibit C. trachomatis-induced FRS2a activation (Figs 4C,
lower panel, and 4D). These experiments confirm that FGFR
activation during C. trachomatis infection is independent of PDGFR
activation.
Using PD173074 or AG1296 singly or in combination, we
examined the effect of blocking FGFR or PDGFR activation on
the efficiency of EB internalization. HeLa cells were pre-incubated
in SFM containing PD173074, AG1296, or both drugs for 2 hrs,
and then infected with C. trachomatis in SFM in the presence of
drug(s). At 1 hpi, the bacterial internalization efficiency (the
fraction of bound EBs that were internalized) was quantified by
inside-out staining as described in Materials and Methods.
Treatment with either drug alone showed a small effect on
internalization that failed to reach statistical significance. Howev-
er, treatment with both drugs showed an additive effect,
decreasing internalization by 40% (p,0.001; Fig 4F). This result
indicates that bacterial entry occurs through redundant pathways
that involve activation of PDGFR and FGFR.
C. trachomatis infection stimulates FGF2 expression,
production, and release from HeLa cells
As host microarray analyses previously revealed that C.
pneumoniae induces fgf2 transcription [32,33], we tested whether
C. trachomatis induces fgf2 transcription. We performed qRT-PCR
with fgf2 specific primers and found that C. trachomatis infection
increased fgf2 mRNA expression 3-fold relative to gapdh at 12 hpi
and 4–5 fold at 24 hpi (Fig 5A); in contrast, no significant increase
in fgf1 expression was detected (Fig S3). Likewise, total FGF2
(secreted and cell associated; measured by ELISA assay) increased
throughout infection (Fig 5B). The increased FGF2 transcription
and production was accompanied by a striking change by 12 hpi
in the distribution of the FGF2 isoforms (Figs 5C and 6A). The
22 kDa, 22.5 kDa, and 24 kDa forms became undetectable in cell
lysates by immunoblot analysis, whereas the 18 kDa form and a
slightly faster migrating form (which likely corresponds to a
previously described 16 kDa secreted form that has similar
biological activities to the 18 kDa form [19]) appeared to increase
in the cell-associated fraction. By 18 hpi, a corresponding increase
in the 16/18 kDa isoforms was detected in the culture medium
(Fig 5C, lower panel).
C. trachomatis induction of fgf2 transcription is mediated
by the Erk1/2 signaling pathway
Diverse stimuli induce fgf2 transcription, including FGF-mediat-
ed activation of FGFR [34] and Erk1/2 activation [35]. As C.
trachomatis infection has been shown to activate Erk1/2
[36,37,38,39,40,41], we tested the role of Erk1/2 in upregulation
of fgf2 transcription. When the kinetics of C. trachomatis-induced
Erk1/2 activation were examined by immunoblot analysis with an
antibody that specifically recognizes the phosphorylated (i.e.
activated) form of Erk1/2, we detected an early peak of Erk1/2
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PLoS Pathogens | www.plospathogens.org 5 October 2011 | Volume 7 | Issue 10 | e1002285Figure 4. Cell associated FGF2 contributes to C. trachomatis L2 binding, activation and recruitment of FGFR/FRS2a, and bacterial
entry. (A) Left panel; HeLa cells were transfected with shRNA to GFP (control) or FGF2. After 72 hr, cell lysates were immunoblotted with anti-FGF2 or
anti-GAPDH (control) to assess efficiency of depletion. The molecular weights of the five FGF2 isoforms (upper panel) and GAPDH (lower panel) are
marked. Right panel; HeLa cells transfected with GFP or FGF2 shRNA were infected with C. trachomatis L2 in SFM and binding was measured at 1 hpi.
Shown is the mean binding 6 SEM compared to GFP shRNA treated cells from three independent experiments. **p,0.01 (B) HeLa cells that were
serum-starved for 2 hr were infected with C. trachomatis L2 for 45 min. Cells were fixed and stained with antibodies to phospho-FGFR (pFGFR; green)
or to phospho-FRS2a (pFRS2a; green). EBs and host cell nuclei were visualized with DAPI (blue). Enlargements of the boxed areas are shown to the
right. Red arrows point to EBs. (C) HeLa cells were incubated in SFM with DMSO, FGFR inhibitor PD173074 (200 nM), PDGFR inhibitor AG1296 (10 mM),
or both inhibitors for 2 hr. Samples were either stimulated with FGF2 (50 ng/mL) for 5 min (upper panel) or infected with C. trachomatis L2 for 45 min
(lower panel) in the presence of the indicated drug. Lysates were immunoblotted with antibodies to pFRS2a or to FRS2a. FRS2a migrates as multiple
bands, delineated by the bracket. Immunoblots are representative of three independent experiments. (D) The percentage of pFRS2a compared to
total FRS2a was quantified using densitometry analysis of the immunoblots (Fig 4C) and normalized to DMSO (DM) treated uninfected samples. The
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phosphorylation beginning at 10 hpi (Fig 6A), consistent with
previously reported results [36,42]. We performed a more detailed
time course of the induction of fgf2 mRNA and found a small but
statistically significant (p,0.05) enhancement of fgf2 transcription as
early as 6–8 hpi, which further increased at 10 hpi (Fig 6B). Thus,
the kinetics of C. trachomatis-induced upregulation of fgf2 transcrip-
tion is consistent with the involvement of Erk1/2 signaling.
To determine whether Erk1/2 activation is necessary for up-
regulation of fgf2 transcription in response to C. trachomatis infection,
we monitored the effect of inhibiting Erk1/2 on fgf2 transcription
during infection (Fig 6C and D). The Erk/MAPK kinase (MEK)
inhibitorU0126 wasadded for the first 3 hrs ofinfection (0–3 hpi; to
prevent the first wave of Erk1/2 activation) or for the last 4 hrs of
infection (8–12 hpi; to prevent the second wave of Erk1/2
activation), and fgf2 transcription was assessed at 12 hpi. Inhibition
of early Erk1/2 activation resulted in an approximately 30%
reduction in fgf2 mRNA levels at 12 hpi, while blocking late Erk1/2
activation decreased fgf2 mRNA levels approximately 60%. These
results suggestthatboth the earlyand late peaksofErk1/2 activation
contribute to the upregulation of fgf2 mRNA observed at 12 hpi.
The reduction in fgf2 transcription by U0126 was not an indirect
consequence of blocking early events in the life cycle, as short-term
treatment with U0126 had no effect on C.trachomatis binding,uptake,
or replication (Figs S4A–C). We noted that the partial decrease in
fgf2 transcriptioninthepresenceoftheMAPKinhibitor(Fig6D)was
not immediately reflected in decreased levels of cell associated FGF2
(Fig 6C). Post-transcriptional regulation could account for this
observation [43,44,45], suggesting that regulation of FGF2 is
complex and subject to multiple levels of control.
Since Erk1/2 activation was previously reported to be
dependent upon C. trachomatis replication [36], we examined
whether bacterial protein synthesis was required for the early and/
or late wave(s) of Erk1/2 activation. The addition of the bacterial
protein synthesis inhibitor chloramphenicol (CAM) did not reduce
Erk1/2 phosphorylation at 45 min pi, suggesting that bacterial
protein synthesis is not required for the early peak of Erk
activation (Fig 6E, left panel). In contrast, addition of CAM to C.
trachomatis-infected cells from 0–12 hpi, 3–12 hpi, or 6–12 hpi
abrogated late Erk1/2 activation, as assessed at 12 hpi (Fig 6E,
right panel). Consistent with its role in late Erk1/2 activation,
inhibition of bacterial protein synthesis partially reduced the
increase in fgf2 transcription at 12 hpi (Fig 6F).
Although FGFR or PDGFR activation are known to activate
Erk1/2 and to enhance fgf2 transcription [46,47,48], pharmaco-
logic inhibition of these growth factor receptors during C.
trachomatis infection only partially blocked Erk1/2 activation at
45 min pi (Fig S5A), did not inhibit Erk1/2 activation at 12 hpi
(data not shown), and had no statistically significant inhibitory
effect on C. trachomatis-mediated induction of fgf2 transcription (Fig
S5B). Together, these results suggest that both waves of C.
trachomatis-mediated Erk1/2 activation contribute to the induction
of fgf2 transcription and that this transcriptional regulation is
independent of FGFR receptor activation.
High molecular weight (HMW) FGF2 isoforms are
degraded during intracellular C. trachomatis replication
We examined whether Erk1/2 activation, bacterial protein
synthesis, and/or host protein synthesis is required for the change
in FGF2 isoforms. Addition of U0126 to C. trachomatis-infected cells
values represent the mean (6 SEM) of three independent experiments. *p,0.05 compared to DMSO treated uninfected cells. (E) The effect of FGF2
depletion by shRNA on co-localization of pFGFR with surface bound EBs was quantified in at least 8 different fields. Shown are the average percent of
EBs that co-localized with pFGFR (6 SEM). ***p,0.001 (F) FGFR and PDGFR have redundant roles in C. trachomatis L2 entry. HeLa cells pre-incubated
in SFM with DMSO, PD173074, AG1296, or both inhibitors for 2 hr were infected with C. trachomatis L2 for 1 hr in the presence of drug in SFM. Cells
were fixed and analyzed by inside-out staining to distinguish between total cell associated bacterial and internalized bacteria as described in
Materials and Methods. The internalization efficiency (the percentage of internalized EBs/total cell associated EBs) in each case was normalized to
DMSO (DM) treated cells. Shown is the mean (6 SEM) of three independent experiments. ***p,0.001 compared to DMSO treated cells
doi:10.1371/journal.ppat.1002285.g004
Figure 5. C. trachomatis L2 infection stimulates FGF2 expres-
sion, production, and release. (A) Total RNA was isolated from the
HeLa cells infected with C. trachomatis L2 for indicated time. fgf2 mRNA
was assessed by qRT-PCR and normalized to gapdh mRNA. (B) Total
FGF2 protein (cell associated and secreted) was measured by
Quantikine kit and normalized to uninfected cells (UI) and normalized
for total cell number by quantifying total LDH activity. (C) Cell lysates
(upper panel) and cell supernatants (lower panel) of FGF2 were
collected from HeLa cells infected with C. trachomatis L2 for the
indicated times. FGF2 was detected by immunoblot (upper panel) or by
immunoprecipitation (lower panel). GAPDH serves as a loading control.
doi:10.1371/journal.ppat.1002285.g005
C. trachomatis Co-opts FGF2 to Enhance Infection
PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002285from 0–3 hpi or from 8–12 hpi had no effect on the change in
FGF2 isoforms (Fig 6C, lower panel). However, addition of CAM
from 0–12 hpi or from 6–12 hpi prevented the change in FGF2
isoforms, suggesting that either de novo synthesis of a bacterial
protein or bacterial growth was required for this FGF2 isoform
change (Fig 6E, right panel). Furthermore, the eukaryotic
translation inhibitor cycloheximide (CHX) did not prevent the
C. trachomatis-induced changes in FGF2 isoforms (Fig 7A),
indicating that these changes occurred at a post-translational step.
The loss of the 22 kDa, 22.5 kDa, and 24 kDa isoforms could
arise through host-mediated degradation or through a secreted
chlamydial protease, such as Chlamydial Protease/proteasome-
like factor (CPAF), a broad spectrum protease [49]. We first tested
whether recombinant CPAF could alter the FGF2 isoform
distribution by incubating recombinant CPAF with uninfected
HeLa cell lysates. No change in the FGF2 isoform distribution was
observed (Fig 7B), although CPAF was active against its known
substrate vimentin (Fig 7B)[50].
We next determined whether host proteosomal enzymes might
be involved in degradation of HMW FGF2 isoforms. Treatment of
cells from 9–12 hpi with the proteosome inhibitors Lactacystin or
MG132 prevented the change in FGF2 isoforms (Fig 7C).
Together, these results suggest that the abrupt change in FGF2
isoforms is independent of Erk1/2 activation, does not involve
CPAF, and likely involves degradation by host proteosomal
proteases activated during C. trachomatis intracellular replication.
It is also possible that an as yet to be identified C. trachomatis
protease that is secreted into the host cell cytosol and that is
inhibited by Lactacystin or MG132 is responsible for the loss of the
HMW FGF2 isoforms.
C. trachomatis induced secretion of FGF2 is caspase-1
independent and may accompany host cell lysis
We were particularly interested in our observation that C.
trachomatis infection increases the secretion of the 16/18 kDa FGF2
isoforms, as these isoforms are important for FGFR activation and
for C. trachomatis binding. These isoforms lack a canonical secretion
signal, and their secretion does not involve the classical ER-Golgi
secretion pathway [51,52]. The mechanism of FGF2 secretion is
incompletely understood; there are reports that FGF2 release is
Figure 6. C. trachomatis L2 induces a biphasic activation of Erk1/2 which contributes to the induction of fgf2 mRNA expression. (A)
Upper 2 panels: Erk1/2 activation in HeLa cells infected with C. trachomatis L2 for the indicated times was examined by immunoblotting cell lyates
with antibodies to phospho-Erk (pERK) and to total Erk. Arrows indicate Erk1/2 (p42/p44). Two peaks of Erk1/2 activation are noted, at 45 min pi and
at 10–12 hpi. Lower 2 panels: The same lysates from upper panel were immunoblotted with antibodies to FGF2 or to GAPDH (loading control). In the
FGF2 immunoblot, arrows indicate the 24, 22.5/22, 18, and 16 kDa isoforms of FGF2. An abrupt change in FGF2 isoforms is noted at 10 hpi. (B) Total
mRNA was isolated from HeLa cells infected with C. trachomatis L2 for the indicated times and the fold change in fgf2 mRNA relative to gapdh mRNA
was measured by qRT-PCR. An increase in fgf2 mRNA is detectable by 6 hpi and increases further at 10–12 hpi. **p,0.01, ***p,0.001, compared to
uninfected (UI) samples. (C, D) HeLa cells were infected with C. trachomatis L2 for 12 hrs in the presence of 10 mM U0126 (U) between 0–3 hpi or 8–
12 hpi. Lysates were immunoblotted with antibodies to pErk or to total Erk. The fold change in fgf2 mRNA relative to gapdh mRNA was quantified by
qRT-PCR using total RNA isolated at 12 hpi. Inhibition of either the early peak of Erk activation or the late peak of Erk activation decreased C.
trachomatis L2 induction of fgf2 mRNA but did not affect the distribution of FGF2 isoforms. **p,0.01, ***p,0.001 compared to C. trachomatis L2
infected cells. (E, F) HeLa cells were infected with C. trachomatis L2 for 45 min or 12 hrs in the absence or presence of chlorampenicol (CAM; 100 mg/
mL) for the indicated times. (E) Erk activation and FGF2 isoforms were detected by immunoblotting cell lyates with the indicated antibody. MOMP
serves as a control for bacterial replication. (F) Total RNA was isolated at 12 hpi and the fold change in fgf2 mRNA relative to gapdh mRNA was
monitored by qRT-PCR. Bacterial protein synthesis is required for Erk activation and for the change in FGF2 isoforms. *p,0.05, ***p,0.001 compared
to uninfected (UI) cells.
doi:10.1371/journal.ppat.1002285.g006
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Na-K ATPase [53,54,55]. Recent studies reported that FGF2 can
be directly translocated across the plasma membrane in a process
which depends on the ability of FGF2 to bind HSPGs and a
transient interaction between FGF2 and phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2) [21].
As C. trachomatis has been shown to induce caspase-1 activation
[56], we tested whether caspase-1 is involved in the C. trachomatis
mediated release of FGF2. C. trachomatis infected cells were stained
with an antibody to p20, one of the two cleavage products of
activated caspase-1. An increase in p20-positive cells was not
detected until 18 hpi and became most marked at 24 hpi (Fig
S6A), consistent with previously published studies showing that C.
trachomatis activation of caspase-1 is a late event in the intracellular
life cycle [56]. Thus, activation of caspase-1 does not correlate
with C. trachomatis-induced FGF2 release seen from 12 hpi.
Likewise, neither of the caspase-1 inhibitors YVAD nor WEHD
altered production (data not shown) or release (Fig S6B) of FGF2
during C. trachomatis infection. Although our studies do not rule out
other active pathways of release, they suggest that the C.
trachomatis-induced release of the FGF2 is likely independent of
caspase-1 activation.
As C. trachomatis infection ultimately leads to host cell death and
lysis [2], we considered the possibility that C. trachomatis-induced
FGF2 release may be a consequence of host cell lysis. As shown in
Fig 8, the kinetics of FGF2 secretion in C. trachomatis-infected cells
correlates with and is proportional to host cell lysis, as determined
by LDH release. Together, these results suggest that one
mechanism by which FGF2 may be released from C. trachomatis-
infected cells is by passive release secondary to C. trachomatis-
induced host cell lysis.
FGF2 release into the media facilitates subsequent
rounds of C. trachomatis infection
Since C. trachomatis infection stimulates FGF2 production and
release from the host cells, we hypothesized that the increase in
released FGF2 may facilitate subsequent rounds of C. trachomatis
infection. We collected filtered conditioned media (CM) from C.
trachomatis-infected HeLa cells at 20 hpi (CT-CM) or from mock-
infected cells (mock-CM; see materials and methods and Fig 9A).
The concentration of FGF2 in the CT-CM was ,50 fold higher
than mock-CM (data not shown). EBs resuspended in CT-CM
enhanced EB binding 3-fold compared to mock-CM (p,0.001;
Fig 9B). To determine whether FGF2 was responsible for the
stimulatory effect of CT-CM, we immunodepleted FGF2 from the
CT-CM using antibodies to FGF2. EB binding in the presence of
FGF2-immunodepleted CT-CM was approximately 50% less
efficient compared to CT-CM that had not been immunodepleted
or that had been immunodepleted with a control goat IgG
antibody or with antibodies to an unrelated growth factor, EGF
(Figs 9C and 9D; P,0.005). To test for the efficiency of
immunodepletion, we measured FGF2 by quantikine assay.
Compared to untreated CT-CM, immunonodepletion with anti-
FGF2 decreased the concentration of FGF2 by 60%, (data not
Figure 7. HMW FGF2 isoforms are degraded by C. trachomatis L2-induced host proteases. (A) HeLa cells were infected with C. trachomatis
L2 for 12 hr. For the indicated samples, cycloheximide (CHX; 100 mM) was present from 8–12 hpi. Lysates were immunoblotted with an antibody to
FGF2 or GAPDH (loading control). (B) Hela cell lysates were incubated with recombinant CPAF under the indicated conditions and the distribution of
FGF2 isoforms was assessed by immunoblotting with an antibody to FGF2. For comparison, the distribution of FGF2 isoforms in C. trachomatis L2-
infected HeLa cells (Inf) at 12 hpi is shown in the right lane. Vimentin serves as a positive control for CPAF activity. GAPDH serves as a loading control.
(C) HeLa cells were infected with C. trachomatis L2 for 12 hrs and treated either with DMSO, MG132 (MG; 15 mM) or Lactacystin (LC; 10 mMo r5 0mM)
from 9–12 hpi. Cell lysates were collected at 9 hpi or 12 hpi as indicated and immunoblotted with antibodies to FGF2, MOMP, (control for bacterial
replication), or GAPDH (loading control).
doi:10.1371/journal.ppat.1002285.g007
Figure 8. C. trachomatis L2-induced FGF2 release correlates with
cell lysis. FGF2 or LDH in the cell lysate or in the supernatant was
measured by FGF2 Quantikine kit or the Cytotox 96 non-radioactive
cytotoxicity assay kit, respectively. Shown is the percentage of FGF2
(black bars) or LDH (grey bars) in the supernatant compared to total.
doi:10.1371/journal.ppat.1002285.g008
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stimulates production and release of FGF2, which can then be co-
opted by C. trachomatis to facilitate additional rounds of infection
and bacterial spread.
C. trachomatis serovar E also co-opts the FGF2 pathway
As serovar E binding has been reported to be variably sensitive
to heparan sulfate [27,57,58], we investigated the role of the FGF2
pathway during epithelial cell infection. We first tested whether
FGF2 can enhance serovar E binding to HeLa cells. Addition of
FGF2 stimulated the binding of renograffin-purified serovar E to
HeLa cells in SFM (Fig 10A and B). FGF2-enhanced binding was
HSPG-dependent since it was inhibited by pretreatment of cells
with heparinase (Fig 10A) or by competitive blocking with heparin
(Fig 10B). Neither of these treatments significantly altered serovar
E binding in the absence of exogenously added FGF2. Although
renograffin-purified serovar E bound to purified FGF2 (Fig 10C),
the binding was less efficient than serovar L2 (21% (Fig 10C)
compared to 50% (Fig 3D). Depletion of endogenous FGF2 failed
to significantly reduce serovar E binding to HeLa cells in the
absence of serum (data not shown), suggesting that endogenous
levels of FGF2 may not be sufficient to stimulate serovar E
binding. Overall, the HSPG-dependence of serovar E appears
qualitatively similar to that of serovar L2, although there are some
quantitative differences.
We next examined whether serovar E infection induced FGF2
transcription, production, secretion, or processing. Serovar E
infection of HeLa cells resulted in induction of fgf2 transcription
within 9 hrs (Fig 10D), biphasic activation of Erk1/2 phosphor-
ylation (with peaks at 45 min and at 12 hrs; Fig 10E), and
processing of the FGF2 isoforms beginning ,12 hpi (Fig 10E).
Conditioned medium harvested from serovar E infected cells at
72 hpi (a time at which host cell lysis commences) was enriched for
the 16/18 kDa isoform of FGF2 (Fig 10F) and stimulated serovar
E binding up to 70% compared to control conditioned medium
(Fig 10G; p,0.001). Thus, at least two different serovars of C.
trachomatis appear to be capable of co-opting the FGF2 pathway to
facilitate bacterial spread.
Figure 9. C. trachomatis L2-induced FGF2 facilitates secondary rounds of infection. (A) Schematic of experiment. HeLa cells were mock-
infected or infected with C. trachomatis L2 for 20 hr in 2% FBS. Conditioned media from mock-infected cells (mock-CM) or from C. trachomatis L2
infected cells (CT-CM) were collected and filtered to remove residual bacteria and cell debris. (B) Renograffin-purified EBs were resuspended in mock-
CM or CT-CM and binding to HeLa cells was measured at 1 hpi. Shown is the mean (6 SEM) of three independent experiments. ***p,0.001
compared to Mock-CM. (C) Filtered CT-CM was immunoprecipitated with goat IgG (control), FGF2 antibody, or EGF antibody and immunoblotted
with FGF2 antibody. The ,24 kDa band in the IgG sample likely represents a breakdown product of IgG light chain (LC). (D) Renograffin-purified EBs
were resuspended with CT-CM that had been immunodepleted (see Panel C) with the indicated antibody and binding to HeLa cells at 1 hpi was
quantified. The values are normalized to EB binding in CT-CM without antibody incubation. Shown is the mean (6 SEM) of three independent
experiments. ***p,0.001 compared to no antibody depletion.
doi:10.1371/journal.ppat.1002285.g009
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trachomatis serovar E either in SFM or in SFM supplemented with FGF2 (100 ng/mL) for 1 hr. Shown is the representative mean binding (6 SEM) from
three independent experiments. **p,0.01. (B) HeLa cells were serum starved for 2 hrs and then infected for 1 hr with C. trachomatis serovar E either
in SFM or in SFM supplemented with FGF2 (100 ng/mL) in the presence or absence of heparin (1 mg/mL). Shown is the representative mean binding
(6 SEM) from three independent experiments. ***p,0.001 (C) Renograffin-purified serovar E EBs were incubated with 100 ng/mL of FGF1 or FGF2 in
SFM containing 0.1% BSA for 1 hr at 37uC. The EB-FGF mixture was centrifuged onto coverslips, fixed, and stained with DAPI (to visualize the EBs) and
FGF1 or FGF2 antibody. Co-localization of EBs with FGF1 or FGF2 was quantified from at least 8 different fields. The data are expressed as a mean
percentage of bacteria associated with FGF (6 SEM) compared to total bacteria. ***p,0.001. (D) Upper 2 panels: Erk1/2 activation in HeLa cells
infected with C. trachomatis serovar E was examined by immunoblotting cell lyates with antibodies to pERK or to total ERK. The 42 and 44 kDa forms
of ERK are indicated by the arrows. Middle panel: Cell lysates were immunoblotted with C. trachomatis MOMP antibody. Lower 2 panels: The change
in cell-associated FGF2 isoforms in HeLa cells infected with C. trachomatis serovar E for the indicated times was assessed by immunoblotting cell
lysates with antibodies to FGF2. GAPDH serves as a loading control. Arrows indicate the 24, 22.5/22, 18, and 16 kDa isoforms of FGF2. An abrupt
change in FGF2 isoforms is noted at 10 hpi. (E) Total mRNA was isolated from HeLa cells infected with C. trachomatis serovar E for the indicated time
and the fold change in fgf2 mRNA relative to gapdh mRNA was measured by qRT-PCR. An increase in fgf2 mRNA is detectable by 9 hpi and increases
further at 12 hpi. ***p,0.001 compared to mock-infected cells. (F) HeLa cells were mock-infected for 72 hrs or infected with C. trachomatis serovar E
in 5% FBS for 24, 48, or 72 hrs. Conditioned media were collected, filtered, immunoprecipitated with FGF2 antibody, and immunoblotted with FGF2
antibody. (G) Renograffin-purified serovar E EBs were resuspended in mock-CM or CM from serovar E infected (CT-CM). Binding to HeLa cells was
measured at 1 hpi. Shown is the representative mean binding (6 SEM) from three independent experiments. ***p,0.001 compared to mock-CM.
doi:10.1371/journal.ppat.1002285.g010
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The molecular details of Chlamydia trachomatis binding, entry, and
spread are incompletely understood. HSPGs are thought to play a
role in the initial binding interactions. Since cell surface HSPGs
facilitate the interactions of many growth factors with their
receptors, we investigated the role of HSPG-dependent growth
factors in C. trachomatis infection. Here, we report the novel finding
that FGF2 is necessary and sufficient to enhance C. trachomatis
binding to host cells in an HSPG-dependent manner. Unexpect-
edly, we found that FGF2 binds directly to EBs, where it may
function as a bridging molecule to facilitate interactions of EBs
with FGFR on the cell surface. Upon EB binding, FGFR is
activated locally and contributes to bacterial uptake into non-
phagocytic cells. We show that C. trachomatis infection stimulates
fgf2 transcription and enhances production and release of FGF2
through a pathway that requires bacterial protein synthesis and
activation of Erk1/2 signaling but that is independent of FGFR
activation. Intracellular replication of the bacteria results in host
proteosome-mediated degradation of the HMW isoforms of FGF2
and increased amounts and release of the LMW isoforms. Finally,
we demonstrate the in vivo relevance of these findings by showing
that conditioned medium from C. trachomatis infected cells is
enriched for FGF2 and that this accounts for its ability to enhance
C. trachomatis infectivity in additional rounds of infection. Together,
these results demonstrate that C. trachomatis utilizes multiple
mechanisms to co-opt the host cell FGF2 pathway to enhance
bacterial infection and spread (Fig 11A).
By several criteria, we found that the binding of FGF2 to EBs
appears to be quite specific. We postulate that FGF2 functions as a
bridging molecule, by binding simultaneously to EB surface
proteins and to HSPGs and/or FGFR on the host cell (Fig 11B).
Co-localization of FGF2 with purified EBs was not diminished by
pre-treatment of EBs with heparinase, suggesting that FGF2
binding to EBs was not mediated by HSPGs. However, EB-FGF2
binding may involve synergistic interactions with OmcB, a cysteine
rich outer membrane protein found in most chlamydial species
that contains a HS binding domain and mediates attachment to
HSPGs [59]. We further show that a consequence of FGF2
binding to EBs is that activated FGFR and FRS2a are recruited to
the site of bacterial binding, facilitating uptake. Activation of
FGFR, however, is not required for the Chlamydia-induced
upregulation of fgf2 transcription, production, processing, and
release.
In previous work, we have shown that phospho-PDGFR co-
localizes with bound EBs, but other growth factor receptors, such
as EGFR, are not recruited [5], suggesting selectivity and
specificity in growth factor receptor recruitment. Although
PDGFR signaling has been shown to stimulate FGFR under
some conditions, we did not find evidence for cross-talk in the
setting of C. trachomatis-induced activation of FGFR in the absence
of serum. However, using informative pharmacologic inhibitors,
we found evidence that the PDGFR and FGFR pathways may
function redundantly in C. trachomatis entry. Growth factor
signaling may also be important at steps downstream of entry,
for example by providing pro-survival signals for the host cell [60].
We found that C. trachomatis infection upregulates FGF2
transcription, production, and secretion. FGF2 transcription and
production were upregulated within the first 12 hpi and continued
for at least 24 hpi. This process was independent of FGFR
activation, but involved biphasic activation of Erk1/2 kinases.
Early Erk1/2 activation was independent of de novo bacterial
protein synthesis. We speculate that the first wave of Erk1/2
activation may involve TARP, a chlamydial type III secreted
protein that is present in EBs and then injected into the host cell
cytoplasm upon bacterial binding. TARP has recently been shown
to bind to SHC1 [42], a Src homology-2 domain containing
protein that is recruited to and phosphorylated by FGFR (and
EGFR) upon its activation and that subsequently mediates Erk1/2
activation [61,62,63]. Thus, recruitment and activation of FGFR
may facilitate or synergize with TARP and other chlamydial
factors to activate Erk1/2 as well as to enhance bacterial
internalization. Indeed, the failure of the FGFR inhibitor
PD173074 to completely block C. trachomatis-induced Erk1/2
activation may result from the redundant involvement of
chlamydial factors, such as TARP, together with the activation
of FGFR. The second peak of Erk1/2 activation required active
bacterial protein synthesis. This finding suggests either that a de
novo synthesized chlamydial protein (as opposed to an immediate
early protein such as TARP) is secreted from the vacuole to
activate the Erk pathway, or that Erk is activated in response to
vacuolar and/or bacterial intracellular growth. In any case, we
conclude that the two waves of Erk1/2 activation, which occur
through separate pathways, contribute to upregulation of FGF2
expression.
Our work also reveals that midway through the chlamydial
intracellular life cycle, there is a loss of the HMW FGF2 isoforms
and a concurrent increase in the LMW isoforms (16/18 kDa). The
change in the spectrum of FGF2 proteins was independent of
Erk1/2 activation but required bacterial intracellular growth. We
favor the idea that the HMW forms are degraded rather than
processed into the 16 and/or 18 kDa form. The molecular identity
of the 16 kDa isoform is currently under investigation, but may
represent a previously reported pepstatin-sensitive acid proteinase
cleavage product [19].
We considered several possible mechanisms for the change in
FGF2 isoforms. First, the change in isoforms could result from a
shift in the translation initiation sites. However, a modified pulse-
chase experiment, in which we followed the isoform distribution
after inhibiting host protein synthesis at 6–12 hpi with cyclohex-
imide, demonstrated that the change in FGF2 isoforms still
occurred, eliminating this possibility. Second, we tested whether
the Chlamydia protease CPAF might be responsible for degrading
or processing the FGF2 isoforms, but in vitro experiments using
recombinant CPAF ruled out this notion. Third, and most likely,
the change in FGF2 isoforms may be a consequence of C.
trachomatis-induced activation of a host protease, as pretreatment
with lactacystin or MG132 prevented the isoform change. In
hematopoietic cells, thrombin has been reported to process the
HMW FGF2 isoforms into an 18 kDa species [64], though this
process seems less likely in epithelial cells that lack thrombin.
However, it is possible that an as yet-identified bacterial-encoded
protease could account for the processing.
Finally, we demonstrate that by enhancing secondary rounds of
infection, C. trachomatis-induced up-regulation of FGF2 is physio-
logically important. Conditioned media from C. trachomatis-infected
cells (CT-CM) stimulated EB binding. Two pieces of evidence
provide support that FGF2 contributed to the activity of the CT-
CM. First, there was an increase in FGF2 levels in CT-CM
compared to CM isolated from mock-infected cells. Second,
immunodepletion of FGF2 from the CT-CM decreased its ability
to stimulate EB binding, whereas depletion with a control
antibody or an irrelevant antibody was without effect. In addition
to stimulating EB binding, we speculate that FGF2 production
enhances secondary rounds of infection by its prosurvival activity.
We found both similarities and differences in the HSPG-
dependence and modulation of FGF2 signaling of serovar E
compared to serovar L2. As observed with L2, serovar E binding to
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but was not affected by depletion of host cell FGF2. Serovar E
bound to FGF2 in vitro, though perhaps less avidly. It is intriguing
to speculate that the absence of a functional heparan sulfate binding
domain in the OmcB surface protein of serovar E [59] may explain
in part the decreased FGF2 binding (Fig 11C). Nonetheless, serovar
E stimulated transcription, production, and processing of FGF2.
Together these results suggest that serovar E activates the Erk
pathway and FGF2 production similarly to serovar L2 and that it
may utilize FGF2/HSPG-dependent pathway for binding. In the
future, it will be interesting to determine whether FGFR signaling is
activated upon serovar E binding.
Figure 11. Working model for how C. trachomatis co-opts the FGF2 signaling pathway to enhance infection. (A) FGF2 binds to EBs and
facilitates attachment and internalization through cell surface HSPG and FGFR. Both early (45 min pi, C. trachomatis replication independent) and late
(10 hpi, C. trachomatis replication dependent) Erk1/2 activation induce fgf2 transcription, resulting in an increase of all FGF2 isoforms. Subsequent
intracellular replication of C. trachomatis activates host cell proteases that lead to the processing and/or loss of the HMW FGF2 isoforms and
increased amounts of the 16 and 18 kDa isoforms. Upon host cell lysis, EBs, along with the 16 and 18 kDa FGF2 isoforms, are released. Released FGF2
binds to EBs and serves as a bridging molecule to enhance subsequent rounds of C. trachomatis binding and entry. This positive feedback loop
between C. trachomatis and FGF2 may enhance the efficiency and spread of subsequent rounds of infection. (B) L2-FGF2 binding may involve
synergistic interactions with OmcB-HSPG interactions. (C) The HSPG-binding domain of OmcB of serovar E is non-functional.
doi:10.1371/journal.ppat.1002285.g011
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emerging theme in bacterial infections. Neisseria gonorrhoeae infection
induces expression, processing and release of amphiregulin, an
epidermal growth factor (EGF) family member that is anti-
apoptotic [65]. H. pylori infection stimulates HB-EGF production,
which may contribute to cancer progression [66]. C. pneumoniae
infection of cultured endothelial cells has been reported to increase
FGF2 and PDGF production, which may be responsible for
smooth muscle cell proliferation and intimal thickening in aortic
tissues, and could account for its potential association with
atherosclerosis [67].
In summary, our results demonstrate that C. trachomatis co-opts
FGF2 to enhance infection and bacterial spread (Fig 11A).
Activation of the Erk1/2 pathway, either at the time of binding
and entry or during subsequent intracellular growth, leads to
increased fgf2 transcription and production. In addition, intracel-
lular growth activates host protease(s), resulting in alterations in
the distribution of FGF2 isoforms and enhanced release of the
secreted forms during host cell lysis. The released FGF2 serves as a
bridging molecule to facilitate subsequent rounds of binding,
entry, and intracellular development. This positive feedback loop
amplifies secondary infection as well as promoting efficient
bacterial spread. FGF2 may play additional roles in the
pathogenesis of chlamydial infection, by potentiating the inflam-
matory response, by inhibiting apoptosis, or by modulating gene
expression [68,69,70]. In the future, it will be interesting to
determine whether FGF2 contributes to pelvic inflammatory
disease and whether other human adapted chlamdyial species,
such as C. pneumoniae, utilize FGF2 to enhance infection.
Materials and Methods
Reagents
Recombinant human FGF1 and FGF2 were purchased from
Invitrogen and Leinko Technology. FGF10, PDGF, EGF, HB-
EGF, VEGF were purchased from R&D systems. Heparin,
Heparinase Cycloheximide, and MG132 (Z-Leu-Leu-Leu-al) were
purchased from Sigma-Aldrich. PD173074 and AG1296 were
purchased form Stemgent and Calbiochem, respectively. Carbox-
yfluorescein FLICA kit was purchased from ImmunocChemistry
Technology. Caspase 1 inhibitors, YVAD and WEHD were
purchased from Biovision and R&D systems, respectively.
Chloramphenicol was purchased from Allstar. shRNA constructs
specific for FGF2 or GFP were obtained from OriGene
Technology. Quantikine kit used to measure FGF2 concentration
was purchased from R&D systems. MEK inhibitor U0126 and the
Cytotox 96 non-radioactive cytotoxicity assay kit used to measure
LDH activity were purchased from Promega. QIAshredder,
RNeasy kit, RNase-free DNase, and cDNA synthesis kit were
purchased from Qiagen. SYBR GreenER qPCR SuperMix was
purchased from Invitrogen.
Antibodies were obtained from the following sources: mouse
anti-Chlamydia FITC conjugate from Meridian Diagnostics; goat
anti-C. trachomatis MOMP and rabbit anti-Chlamydia LPS from
Fitzgerald; mouse anti-GAPDH from Chemicon; mouse anti-
FGFR1, mouse anti-FGFR2, rabbit anti-phospho-FGFR (Y653/
654), normal goat IgG, goat anti-FGF2, and goat anti-EGF from
R&D systems; rabbit anti-FRS2a from Santa Cruz Biotechnology;
rabbit anti-phospho FRS2a (Y436), rabbit anti-Erk1/2, and
mouse anti-phospho Erk1/2 (Y202/Y204) from Cell signaling
technology; goat anti-human EGF from R&D systems; mouse
anti-vimentin from Sigma-Aldrich; rabbit anti-caspase-1 from
Biovision; HSPG-10E4 antibody from Seikagaku corp.; HRP-
rabbit anti-goat IgG from Zymed; HRP-goat anti-rabbit IgG and
goat anti-mouse IgG HRP from Amersham Biosciences; all
fluorescently labeled secondary antibodies and phalloidin from
Molecular Probes.
Cell culture and C. trachomatis propagation
HeLa 229 cells and L929 cells were obtained from ATCC and
passaged as previously described [71]. H292 cells were a gift from
Dr. Lemjabbar-Alaoui (UCSF). C. trachomatis serovar L2 (LGV
434) was propagated in L929 cells grown in suspension culture and
purified using a renograffin step-gradient as previously described
[72]. C. trachomatis serovar E, a gift from Dr. Wyrick (East
Tennessee State University), was propagated and purified as
described previously with the following modifications [27]. C.
trachomatis serovar E was grown in semiconfluent HeLa cells for
48 hrs in MEM supplemented with 10% FBS and cycloheximide
(2 mg/mL). Cell monolayers were scraped with plunger and then
sonicated. Cell debris was removed by centrifugation, and
chlamydiae were purified using a renograffin step-gradient as
previously described [72]. The final L2 or serovar E pellet was
resuspended in sucrose phosphate buffer (SPG; 5 mM glutamine,
0.2 M sucrose. 0.2 M phosphate buffer) and stored at 280uC.
IF studies
IF was carried out as previously described [5]. For each set of
experiments, the exposure times were identical for all images.
Images were analyzed with Metamorph (Molecular devices) or
with Adobe Photoshop CS4 to count nuclei, EBs, or vacuoles. For
all image analysis, a minimum of 8 fields was analyzed per
treatment. Data were compiled from at least 3 independent
experiments unless it is specified.
To determine colocalization of phosphorylated FGFR or
FRS2a with EBs, HeLa cells were grown on glass coverslips in
24-well plates and infected with C. trachomatis for 45 min. Cells
were fixed in 4% paraformaldehyde (PFA), permeabilized with
0.2% Triton, blocked in 1% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS), and incubated with rabbit anti-
phospho-FGFR or anti-phospho-FRS2a for 1 hr. Cells were
washed with three times with PBS and then incubated for 1 hr
with Alexa-488 conjugated secondary antibody and in some cases
with fluorophore-conjugated phalloidin.
Quantitation of C. trachomatis binding and vacuole
formation
HeLa cells were grown on glass coverslips in 24-well plates in
MEM containing 10% FBS overnight, and were infected with C.
trachomatis at an MOI of 2–3 (for quantitation of vacuole
formation) or 10 (for quantitation of EB binding) in the presence
or absence of FBS for 1 hr. For quantitation of binding, unbound
bacteria were removed by washing three times with PBS, and the
infected cells were fixed with 4% PFA for 30 min. For quantitation
of vacuole formation, PBS-washed cells were incubated in fresh
MEM containing 10% FBS for 20 hr. The cells were fixed and
were permeabilized with 0.2% Triton X-100 for 15 min, followed
by blocking in 2% FBS/1% Fish Skin Gelatin in PBS for 30 min.
Bound EBs or vacuoles were visualized by staining with anti-
Chlamydia MOMP antibody followed by staining with Alexa-488
conjugated secondary antibody. The host cell was visualized by
staining the actin cytoskeleton with phalloidin-Alexa 594. Images
were acquired and analyzed as described above. Data was
presented as number of cell-associated EBs per cell or number
of vacuoles per cell.
To analyze the effect of growth factors on C. trachomatis binding,
HeLa cells were serum starved for 2 hrs and then infected with C.
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(100 ng/mL). Binding and vacuole formation were measured at
1 hpi and 20 hpi, respectively. For heparinase treatment, HeLa
cells grown on glass coverslips in 24-well plates were incubated
with 1 unit of heparinase (Sigma) in 0.5 mL of MEM containing
0.1% BSA at 37uC for 2 hr. Enzyme-treated cells were washed
three times with PBS, infected with C. trachomatis, and then
analyzed as described above. The efficacy of heparinase treatment
was examined by IF staining with 10E4 antibody, which
recognizes HW N-sulfation.
Analysis of growth factor binding to purified EBs
FGF1 or FGF2 (100 ng/mL) was added to renograffin purified
EBs (1610
7 IFU) suspended 1 mL of MEM containing BSA
(0.1%), incubated with gentle agitation for 1 hr at 37uC,
transferred to coverslips in 24-well plates, and centrifuged at
1000 rpm for 10 min. Unbound bacteria were removed by
washing three times with PBS. EBs were visualized by staining
with DAPI. FGF was visualized by staining with goat anti-FGF1 or
anti-FGF2 antibody followed by staining with Alexa-488 conju-
gated secondary antibody. In some case, EBs (1610
7 IFU) was
pretreated heparinase 1 unit in 0.5 mL of MEM containing 0.1%
BSA at 37uC for 2 hr before incubating with FGF2. To examine
the specificity of the C. trachomatis-FGF2 interaction, goat IgG or
goat anti-FGF2 antibody (2 mg/mL) was added to the mixture of
EBs-FGF2 and incubated for 1 hr rotating in 37uC. Data is
presented as percentage of EB associated with FGF1 or FGF2
relative to total EB.
shRNA depletion
HeLa cells grown in 6-well plates were transfected with the
indicated shRNA according to manufacturer’s protocol. At 48 hrs
post transfection, the cells were trypsinized and reseeded onto glass
coverslips in 24-well plates. At 72 hrs post transfection, cells were
infected with C. trachomatis in SFM for 1 hr and then fixed. Lysates
from shRNA-treated cells were immunoblotted with antibodies to
FGF2 to determine the efficiency of FGF2 depletion.
Immunoblot analysis
HeLa cells were lysed for 15 min on ice in Lysis Buffer (50 mM
Tris HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 50 mM NaF, 1% sodium deoxycholate, 0.1% SDS, 1 mM
sodium orthovanadate, 0.1 mM okadaic acid, and Complete
protease inhibitors (Roche Diagnostics)). Cell lysates were
collected, centrifuged at 20,800 g for 15 min to remove cell
debris, and the supernatant was boiled in NuPage 4X LDS sample
buffer (Invitrogen) with 100 mM DTT for 10 min. Proteins in the
supernatant were separated on 10% NuPAGE Novex Bis-Tris gels
(Invitrogen) and transferred to 0.45 mm Trans-blot nitrocellulose
membranes (BioRad Laboratories). Membranes were rinsed in
water, followed by blocking with 3% milk (Upstate) in Tris-
buffered saline (TBS) for 1 hr. Each membrane was incubated
with the indicated antibody in 3% milk in TBS with 0.02%
Tween-20 (TBST) overnight at 4uC, followed by an incubation
with the appropriate HRP-conjugated antibodies for 1 hr. HRP-
conjugated antibodies were detected by ECL (Amersham
Biosciences) according to the manufacturer’s protocol. For
quantification, band intensity was analyzed using Metamorph
image analysis software (Molecular devices, Sunnyvale, CA).
Inside-out staining
Inside-out staining was performed as described previously [5]
with the following modifications. HeLa cells grown overnight on
glass coverslips in 24-well plates were infected with C. trachomatis
for 1 hr at 37uC. Cells were washed three times with PBS to
remove unbound bacteria and then fixed in 1% PFA for 15 min,
conditions under which the host cell plasma membrane is not
permeabilized. After fixation, cells were blocked in 2% FBS/1%
FSG/PBS for 30 min and then incubated with goat anti-MOMP
antibody for 1 hr followed by incubation with donkey anti-goat
Alexa 488 antibody to stain external EBs. Cells were then
permeabilized with 0.2% Triton X-100 for 15 min, blocked in 2%
FBS/1% FSG/PBS for 30 min again, and incubated with rabbit
anti-Chlamydia LPS antibody followed by incubation with goat
anti-rabbit Alexa 594 antibody to stain both intracellular and
extracellular EBs. The host cells were visualized by staining the
actin cytoskeleton with phalloidin-Alexa 350. All images were
acquired and analyzed as described in Immunofluorescence
studies. The percent efficiency of internalization was calculated
as follows: (number of total cell associated EB-number of
extracellular EB)/(number of total cell associated EB)6100.
In vitro recombinant CPAF studies
HeLa cells grown in T-75 flask at ,100% confluency (8.4610
6
cells) were harvested and lysed in 200 mL 50 mM Tris buffer
(pH 7.5) with 1X protease inhibitory cocktail (Roche) and 5 mM
PMSF. Cell lysates were sonicated gently and centrifuged at
10,600 X g for 5 min at 4uC. Supernatants were split into four
samples (,50 mL each). Purified recombinant CPAF (a kind gift of
Dr. Raphael Valdivia) was added to three samples and incubated
for 30 min at 4uC, 10 min at 37uC, or 30 min at 37uC. Incubation
without CPAF for 30 min at 37uC served as a negative control.
Samples were boiled with NuPage LDS sample buffer (Invitrogen)
and immunoblotted with antibodies to FGF2, vimentin, or
GAPDH.
Measuring FGF2 concentration and LDH activity
HeLa cells grown in 24-well plate were infected with C.
trachomatis for 1 hr, washed, and then incubated in 0.5 mL media
containing 2% FBS for the indicated times. At the end of
incubation, C. trachomatis-conditioned media (CT-CM), control
conditioned medium (Mock-CM), and cell lysates were collected.
The supernatants were centrifuged at 1000 rpm to remove cell
debris and filtered through a 0.22 mm filter to remove any EBs.
The mock or L2 infected cells were washed once with PBS, lysed
with 0.5 mL lysis buffer, centrifuged for 10 min at 20,800 X g, and
then the supernatants were collected. FGF2 concentration in CT-
CM and Mock-CM were measured using the Quantikine kit
according to manufacturer’s protocol. Total FGF2 represents the
FGF2 concentration of the cell lysate and the supernatant. The
percentage of released FGF2 was calculated as released FGF2/
total FGF2.
Portions of the supernatant and cell lysate were diluted and
quantified for LDH activity using the Cytotox-96 kit according to
manufacturer’s protocol. Total LDH activity (cell associated plus
released) or released LDH activity was calculated as described
above.
Caspase-1 activation
C. trachomatis infected HeLa cells were labeled with FAM-
YVAD-fmk caspase-1 FLICA kit according to the manufacturer’s
protocol at 12, 18, or 24 hpi. Hoechst dye was used to stain the
host cell nuclei during the last 5 min of incubation of FLICA
reagents. Excess dye was removed by washing three times with
PBS and IF images of live cells were taken immediately. The
percentage of FLICA positive cells relative to the total cell number
was calculated.
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FGF2 release, C. trachomatis-infected HeLa cells were incubated
with DMSO, YVAD (100 mM), or WEHD (100 mM) from 12 hpi
to 24 hpi. The ratios of FGF2/LDH activity in the supernatant in
the presence of inhibitors were measured as described above and
compared to the ratio in control (DMSO-treated) cells.
Isolation of RNA and DNA, cDNA synthesis, and Real Time
PCR
RNAs from uninfected and Chlamydia-infected HeLa cells were
isolated using the QIAshredder and the RNeasy kit according to
the manufacturer’s instructions. RNA was treated with RNase-free
DNase according to the manufacturer’s instruction. RNA
concentrations were measured using Nanodrop Spectrophotome-
ter (Thermo-scientific). One mg of RNA was reverse transcribed
using cDNA synthesis kit in a 20 mL reaction. Quantitative PCR
(qPCR) was performed with 2 mL of the cDNA preparation using
SYBR GreenER qPCR SuperMix in a 25 mL reaction using DNA
Engine Opticon-2 Real-Time PCR Detection System in the
Opticon-2 Real-Time Cycler (BioRad). Primers for human gapdh
were 59-CTTCTCTGATGAGGCCCAAG-39 forward and 59-
GCAGCAAACTGGAAAGGAAG-39 reverse. Primers for human
fgf2 were 59-CGTGCTATGAAGGAAGATGGA39 forward and
59-TGCCCAGTTCGTTTCAGT-39 reverse. qPCR included
initial denaturation at 94uC for 10 min, followed by 35 cycles of
94uC for 10 s, 53uC for 15 s, 72uC for 20 s, 72uC for 1 s and then
72uC for 10 min followed by a dissociation curve every 0.5uC from
55uCt o9 5 uC. In a dissociation curve, a single peak was confirmed
in each of the amplified sequences. For the quantification of fgf2
expression relative to gapdh in different samples, the threshold cycle
(Ct) values of targets were expressed as 2
2DDCt (fold) as described
previously [73]. Each sample was additionally amplified without
reverse transcription reaction to confirm the absence of contam-
inating DNA in the RNA sample.
For quantitative PCR of Chlamydia groEL relative to human
gapdh, DNA from infected and uninfected Hela cells was isolated
using the Gentra Puregene kit (Qiagen) according to the
manufacturer’s instructions. qPCR was performed with 100 ng
of RNase treated DNA. The primers for Chlamydia groEL were 59-
GCTCATCTTCATTAGTCAACATTGG-39 forward and 59-
CTCTCTGGTGGAGTAGCAGTCATT-39 reverse. The qPCR
cycle included 2 min at 50uC, 10 min at 94uC, followed by 35
cycles of 94uC for 15 s, 57uC for 45 s, and 72uC for 20 s. After the
cycle, it was followed by a dissociation curve every 0.5uC from
55uCt o9 5 uC. Relative gene copies of groEL to gapdh was expressed
as 2
2DDCt (fold) as described above.
Conditioned media
HeLa cells grown in 6-well plates were mock-infected or
infected with C. trachomatis for 1 hr. Unbound bacteria were
removed by washing three times with PBS, and infected cells were
incubated in 1 mL of media containing 2% FBS for 20 hrs. At the
end of incubation, the conditioned media from mock-infected cells
(Mock-CM) or C. trachomatis infected cells (CT-CM) was collected
and centrifuged 5 min at 240 X g. The CM was passed through a
0.22 mm filter to remove any residual EBs. EBs were resuspended
in filtered Mock-CM or CT-CM and vacuole formation was
quantified at 18 hpi.
For immunoprecipitation of FGF2, the filtered MOCK-CM or
CT-CM was incubated for 2 hrs with 4 mg of anti-FGF2 goat IgG
preconjugated to 50 mL of Protein G Sepharose TM 4 Fast Flow
(GE HealthCare) at 4uC. Immunoprecipitates were recovered by
centrifugation at 1 min at 1000 rpm. The immunoprecipitates
were boiled in LDS sample buffer containing 100 mM dithio-
threitol and then subjected to immunoblotting to detect FGF2.
For immunodepletion of FGF2, the filtered CT-CM was
depleted with normal goat IgG (R&D system), anti-FGF2 goat
IgG, or anti-EGF goat IgG preconjugated to Protein G Sepharose
TM 4 Fast Flow (GE HealthCare). Supernatants were collected
after centrifugation and used for further infection. Immunopre-
cipitates were recovered and subjected to immunoblotting as
mentioned above to ensure FGF2 or EGF depletion.
Statistical analysis
Data represented the mean 6 standard error of at least
experiments. Statistical analysis was performed using the software
program InStat. The significance between groups was determined
by ANOVA. p,0.05 was considered to be statistically significant.
Gene IDs
FGF1 (2246), FGF2 (2247), FGF10 (2255), FGFR1 (2260),
FGFR2 (2263), FGFR3 (2261), FGFR4 (2264), FRS2a (10818),
ERK-1 (5595), ERK-2 (26413), PDGFR-b (5159), PDGF-B
(18591), EGF (1950), HB-EGF (1839), and VEGF (7422).
Supporting Information
Figure S1 FGF2 stimulates C. trachomatis L2 binding in
a do\se-dependent, saturable manner. (A) HeLa cells were
serum starved for 2 hrs and then infected with C. trachomatis L2 in
SFM supplemented with the indicated concentration of FGF2 for
1 hr. Binding was quantified at 1 hpi. Shown is the mean number
of EBs bound per cell (6 SEM), representative of two independent
experiments. (B) FGF2 stimulates C. trachomatis vacuole formation
in H292 cells. H292 cells were serum starved for 2 hr and then
infected with C. trachomatis L2 in SFM or in SFM supplemented
with FGF2 (100 ng/mL). Vacuole formation was quantified at
20 hpi. Shown is the mean 6 SEM, representative of two
independent experiments. *** p,0.001
(TIF)
Figure S2 Heparinase treatment of HeLa cells de-
creased surface staining with an anti-heparan sulfate
(10E4) antibody. (A) Hela cells pretreated with heparinase (1
unit) for 2 hrs were fixed and stained with anti-heparan sulfate
(10E4) Ab (green) and DAPI (blue). Shown are 4 representative
fields. (B) Total Heparan sulfate signal per cell was measured using
Metamorph image analysis software, and is expressed as arbitrary
units (AU). Shown is the average value of at least 6 different fields
(6 SEM). *p,0.05
(TIF)
Figure S3 C. trachomatis L2 infection does not stimu-
lates fgf1 transcription. Total RNA was isolated from the
HeLa cells infected with C. trachomatis at the indicated times post
infection. fgf1 mRNA was assessed by qRT-PCR and normalized
to gapdh mRNA. Data shown is representative of two independent
experiments.
(TIF)
Figure S4 Erk1/2 activation is not necessary for C.
trachomatis L2 binding, internalization, or replication.
(A,B) HeLa cells were infected with C. trachomatis L2 for 1 hr in
FBS-containing media supplemented with DMSO or U0126
(10 mM). Bound or internalized EBs were quantified by inside-out
staining as described in Materials and Methods. Internalization
efficiency is expressed as a mean percentage 6 SEM of
internalized EBs compared to total cell associated EBs. Data
shown is representative of three independent experiments. (C)
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indicated, U0126 (U, 10 uM) was present for the first 3 hpi (I+U
0–3 h) or the last 4 hpi (I+U 8–12 h). Total DNA was isolated and
C. trachomatis L2 replication was assessed by qPCR of groEL relative
to gapdh DNA.
(TIF)
Figure S5 FGFR activation contributes to C. trachoma-
tis L2-induced early Erk1/2 activation but is not
required for up regulation of fgf2 transcription. HeLa
cells were infected with C. trachomatis L2 in SFM supplemented
with DMSO (DM), PD173074 (PD; 200 nM), AG1296 (AG;
10 mM), or both (P/A). (A) Cell lysates were collected at 45 min pi
and were immunoblotted with antibodies to phospho-Erk1/2,
total Erk1/2, or GAPDH (loading control). Immunoblots are
representative of three independent experiments. (B) HeLa cells
were infected for 12 hrs. Inhibitors were present for the first 2 hrs.
Total mRNA was isolated at 12 hpi and the fold change in fgf2
mRNA relative to gapdh mRNA was measured by qRT-PCR. The
results are normalized to uninfected cells (UI). Shown is the mean
6 SEM representative of three independent experiments.
(TIF)
Figure S6 Caspase-1 activation is not required for C.
trachomatis L2 -stimulated FGF2 release. (A) HeLa cells
were infected with C. trachomatis L2 for the indicated times. During
the last hour of infection, cells were labeled with FAM-YVAD-fmk
caspase-1 as described in the Materials and Methods. Shown is the
percentage of FLICA positive cells among ,5000 cells. (B) HeLa
cells were infected with C. trachomatis L2 for 24 hrs in the presence
of DMSO, YVAD or WEHD between 12–24 hpi. Secreted FGF2
was quantified in the media. Results are normalized to DMSO-
treated cells. Shown is the mean 6 SEM representative of 3
independent experiments.
(TIF)
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